Omesdafexor is under clinical development by Metacrine and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Omesdafexor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Omesdafexor (MET-409) is under development for the treatment of type 2 diabetes, irritable bowel syndrome with diarrhea and inflammatory bowel diseases like ulcerative colitis and Crohn's disease. It is administered orally. The drug candidate acts by targeting farnesoid X activated receptor (FXR). It was under development for treatment of non-alcoholic steatohepatitis (NASH).
Metacrine is a clinical-stage biopharmaceutical company that focuses on the development of therapies for the treatment of patients with liver and gastrointestinal diseases. The company develops its proprietary portfolio of non-bile acid FXR agonists through its chemistry and biology platform. Its lead program includes MET409, a next-generation farnesoid X receptor (FXR) agonist intended for the treatment of non-alcoholic steatohepatitis, irritable bowel syndrome with diarrhea and inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. The company also develops a pipeline of drug candidates for the treatment of inflammation and fibrosis. Metacrine is headquartered in San Diego, California, the US.
For a complete picture of Omesdafexor’s drug-specific PTSR and LoA scores, buy the report here.